Literature DB >> 32986223

Germline variants of Brazilian women with breast cancer and detection of a novel pathogenic ATM deletion in early-onset breast cancer.

Gabriel Bandeira1, Katia Rocha1, Monize Lazar1, Suzana Ezquina1, Guilherme Yamamoto1,2, Monica Varela1, Vanessa Takahashi1, Meire Aguena1, Thomaz Gollop3, Mayana Zatz1, Maria Rita Passos-Bueno1, Ana Krepischi1, Oswaldo Keith Okamoto4.   

Abstract

BACKGROUND: It is estimated that 5-10% of breast cancer cases are hereditary. The identification of pathogenic germline variants allows individualized preventive health care, improvement of clinical management and genetic counseling. Studies in ethnically admixed Latin American populations have identified regions with increased frequency of deleterious variants in breast cancer predisposing genes. In this context, the Brazilian population exhibits great genetic heterogeneity, and is not well represented in international databases, which makes it difficult to interpret the clinical relevance of germline variants.
METHODS: We evaluated the frequency of pathogenic/likely pathogenic (P/LP) germline variants in up to 37 breast cancer predisposing genes, in a cohort of 105 breast and/or ovarian cancer Brazilian women referred to two research centers between 2014 and 2019.
RESULTS: A total of 22 patients (21%) were found to carry P/LP variants, and 16 VUS were detected in 15 patients (14.3%). Additionally, a novel pathogenic ATM intragenic deletion was identified in an early-onset breast cancer. We also detected a BRCA1 pathogenic variant (c.5074+2T>C) in higher frequency (10×) than in other studies with similar cohorts.
CONCLUSIONS: Our findings contribute to the characterization of the genetic background of breast cancer predisposition in the Brazilian population as a useful resource to discriminate between deleterious variants and VUS, thus enabling improvement in the preventive health care and clinical management of carriers.

Entities:  

Keywords:  ATM; BRCA1; BRCA2; Breast and ovarian cancer susceptibility; Hereditary breast and ovarian cancer (HBOC)

Year:  2020        PMID: 32986223     DOI: 10.1007/s12282-020-01165-1

Source DB:  PubMed          Journal:  Breast Cancer        ISSN: 1340-6868            Impact factor:   4.239


  30 in total

1.  A portrait of germline mutation in Brazilian at-risk for hereditary breast cancer.

Authors:  Ana Rafaela de Souza Timoteo; Ana Élida Menezes Magalhães Gonçalves; Lucas Amadeus Porpino Sales; Betina Menezes Albuquerque; Jorge Estefano Santana de Souza; Patrícia Cristina Pascoto de Moura; Marcos Alberto Arruda de Aquino; Lucymara Fassarela Agnez-Lima; Tirzah Braz Petta Lajus
Journal:  Breast Cancer Res Treat       Date:  2018-08-29       Impact factor: 4.872

2.  What Is the Best Treatment of Locally Advanced Nasopharyngeal Carcinoma? An Individual Patient Data Network Meta-Analysis.

Authors:  Laureen Ribassin-Majed; Sophie Marguet; Anne W M Lee; Wai Tong Ng; Jun Ma; Anthony T C Chan; Pei-Yu Huang; Guopei Zhu; Daniel T T Chua; Yong Chen; Hai-Qiang Mai; Dora L W Kwong; Shie-Lee Cheah; James Moon; Yuk Tung; Kwan-Hwa Chi; George Fountzilas; Jean Bourhis; Jean Pierre Pignon; Pierre Blanchard
Journal:  J Clin Oncol       Date:  2016-12-05       Impact factor: 44.544

Review 3.  Hereditary breast and ovarian cancer: new genes in confined pathways.

Authors:  Finn Cilius Nielsen; Thomas van Overeem Hansen; Claus Storgaard Sørensen
Journal:  Nat Rev Cancer       Date:  2016-08-12       Impact factor: 60.716

4.  Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.

Authors:  Freddie Bray; Jacques Ferlay; Isabelle Soerjomataram; Rebecca L Siegel; Lindsey A Torre; Ahmedin Jemal
Journal:  CA Cancer J Clin       Date:  2018-09-12       Impact factor: 508.702

5.  Prevalence of BRCA1/BRCA2 mutations in a Brazilian population sample at-risk for hereditary breast cancer and characterization of its genetic ancestry.

Authors:  Gabriela C Fernandes; Rodrigo A D Michelli; Henrique C R Galvão; André E Paula; Rui Pereira; Carlos E Andrade; Paula S Felicio; Cristiano P Souza; Deise R P Mendes; Sahlua Volc; Gustavo N Berardinelli; Rebeca S Grasel; Cristina S Sabato; Danilo V Viana; Edmundo C Mauad; Cristovam Scapulatempo-Neto; Banu Arun; Rui M Reis; Edenir I Palmero
Journal:  Oncotarget       Date:  2016-12-06

6.  Transient Inhibition of FGFR2b-ligands signaling leads to irreversible loss of cellular β-catenin organization and signaling in AER during mouse limb development.

Authors:  Soula Danopoulos; Sara Parsa; Denise Al Alam; Reza Tabatabai; Sheryl Baptista; Caterina Tiozzo; Gianni Carraro; Matthew Wheeler; Guillermo Barreto; Thomas Braun; Xiaokun Li; Mohammad K Hajihosseini; Saverio Bellusci
Journal:  PLoS One       Date:  2013-10-22       Impact factor: 3.240

7.  Hereditary breast and ovarian cancer: assessment of point mutations and copy number variations in Brazilian patients.

Authors:  Felipe C Silva; Bianca Cg Lisboa; Marcia Cp Figueiredo; Giovana T Torrezan; Erika Mm Santos; Ana C Krepischi; Benedito M Rossi; Maria I Achatz; Dirce M Carraro
Journal:  BMC Med Genet       Date:  2014-05-15       Impact factor: 2.103

8.  BRCA1 and BRCA2 mutational profile and prevalence in hereditary breast and ovarian cancer (HBOC) probands from Southern Brazil: Are international testing criteria appropriate for this specific population?

Authors:  Bárbara Alemar; Cleandra Gregório; Josef Herzog; Camila Matzenbacher Bittar; Cristina Brinckmann Oliveira Netto; Osvaldo Artigalas; Ida Vanessa D Schwartz; Jordy Coffa; Suzi Alves Camey; Jeffrey Weitzel; Patricia Ashton-Prolla
Journal:  PLoS One       Date:  2017-11-21       Impact factor: 3.240

9.  The germline mutational landscape of BRCA1 and BRCA2 in Brazil.

Authors:  Edenir Inêz Palmero; Dirce Maria Carraro; Barbara Alemar; Miguel Angelo Martins Moreira; Ândrea Ribeiro-Dos-Santos; Kiyoko Abe-Sandes; Henrique Campos Reis Galvão; Rui Manuel Reis; Cristiano de Pádua Souza; Natalia Campacci; Maria Isabel Achatz; Rafael Canfield Brianese; Maria Nirvana da Cruz Formiga; Fabiana Baroni Makdissi; Fernando Regla Vargas; Anna Cláudia Evangelista Dos Santos; Hector N Seuanez; Kelly Rose Lobo de Souza; Cristina B O Netto; Patrícia Santos-Silva; Gustavo Stumpf da Silva; Rommel M R Burbano; Sidney Santos; Paulo Pimentel Assumpção; Izabel Maria Monteiro Bernardes; Taisa Manuela Bonfim Machado-Lopes; Thais Ferreira Bomfim; Maria Betânia Pereira Toralles; Ivana Nascimento; Bernardo Garicochea; Sergio D Simon; Simone Noronha; Fernanda Teresa de Lima; Anisse Marques Chami; Camila Matzenbacher Bittar; Jose Bines; Osvaldo Artigalas; Maria Del Pilar Esteves-Diz; Tirzah Braz Petta Lajus; Ana Carolina Leite Vieira Costa Gifoni; Rodrigo S C Guindalini; Terezinha Sarquis Cintra; Ida V D Schwartz; Pricila Bernardi; Diego Miguel; Sonia Tereza Dos Santos Nogueira; Josef Herzog; Jeffrey N Weitzel; Patricia Ashton-Prolla
Journal:  Sci Rep       Date:  2018-06-15       Impact factor: 4.379

10.  The Effect of Abemaciclib Plus Fulvestrant on Overall Survival in Hormone Receptor-Positive, ERBB2-Negative Breast Cancer That Progressed on Endocrine Therapy-MONARCH 2: A Randomized Clinical Trial.

Authors:  George W Sledge; Masakazu Toi; Patrick Neven; Joohyuk Sohn; Kenichi Inoue; Xavier Pivot; Olga Burdaeva; Meena Okera; Norikazu Masuda; Peter A Kaufman; Han Koh; Eva-Maria Grischke; PierFranco Conte; Yi Lu; Susana Barriga; Karla Hurt; Martin Frenzel; Stephen Johnston; Antonio Llombart-Cussac
Journal:  JAMA Oncol       Date:  2020-01-01       Impact factor: 31.777

View more
  3 in total

1.  Detection of germline variants in Brazilian breast cancer patients using multigene panel testing.

Authors:  Rodrigo Santa Cruz Guindalini; Danilo Vilela Viana; João Paulo Fumio Whitaker Kitajima; Vinícius Marques Rocha; Rossana Verónica Mendoza López; Yonglan Zheng; Érika Freitas; Fabiola Paoli Mendes Monteiro; André Valim; David Schlesinger; Fernando Kok; Olufunmilayo I Olopade; Maria Aparecida Azevedo Koike Folgueira
Journal:  Sci Rep       Date:  2022-03-09       Impact factor: 4.379

2.  Germline Testing in a Cohort of Patients at High Risk of Hereditary Cancer Predisposition Syndromes: First Two-Year Results from South Italy.

Authors:  Francesco Paduano; Emma Colao; Fernanda Fabiani; Valentina Rocca; Francesca Dinatolo; Adele Dattola; Lucia D'Antona; Rosario Amato; Francesco Trapasso; Francesco Baudi; Nicola Perrotti; Rodolfo Iuliano
Journal:  Genes (Basel)       Date:  2022-07-21       Impact factor: 4.141

3.  Hereditary Breast Cancer in the Brazilian State of Ceará (The CHANCE Cohort): Higher-Than-Expected Prevalence of Recurrent Germline Pathogenic Variants.

Authors:  Ana Carolina Leite Vieira Costa Gifoni; Markus Andret Cavalcante Gifoni; Camila Martins Wotroba; Edenir Inez Palmero; Eduardo Leite Vieira Costa; Wellington Dos Santos; Maria Isabel Achatz
Journal:  Front Oncol       Date:  2022-07-22       Impact factor: 5.738

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.